Showing papers in "European Urology in 2019"
••
New York University1, Lunenfeld-Tanenbaum Research Institute2, Northwood University3, Ghent University Hospital4, Johns Hopkins University School of Medicine5, Brigham and Women's Hospital6, Paris Descartes University7, Cornell University8, University of Fribourg9, University of Cincinnati Academic Health Center10, Yale University11
TL;DR: The PI-RADS Steering Committee, using a consensus-based process, has recommended several modifications to PI- RADS v2, maintaining the framework of assigning scores to individual sequences and using these scores to derive an overall assessment category.
1,053 citations
••
Umeå University1, Université Paris-Saclay2, Sheba Medical Center3, University of Rennes4, Utrecht University5, Charles University in Prague6, Hannover Medical School7, Royal Free Hospital8, Aberdeen Royal Infirmary9, University of Coimbra10, Queen Mary University of London11, Ludwig Maximilian University of Munich12, University of Eastern Piedmont13, Royal Free London NHS Foundation Trust14
TL;DR: These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019 and are thoroughly evaluated to establish international standards for the care of kidney cancer patients.
965 citations
••
Medical University of Vienna1, Charles University in Prague2, University of Regensburg3, Pierre-and-Marie-Curie University4, Royal Surrey County Hospital5, Autonomous University of Barcelona6, Netherlands Cancer Institute7, University of Paris8, European Association of Urology9, Medical University of Graz10, First Faculty of Medicine, Charles University in Prague11, Royal Free London NHS Foundation Trust12, University of Rennes13
TL;DR: The European Association of Urology Non-muscle-invasive Bladder Cancer (NMIBC) Panel has released an updated version of their guidelines, which contains information on classification, risk factors, diagnosis, prognostic factors, and treatment of NMIBC.
897 citations
••
TL;DR: Smoking, obesity, hypertension, and hypertension are most strongly associated with RCC, and the cost effectiveness of a screening programme needs to be assessed on a country-specific level due to geographic heterogeneity in incidence and mortality rates, costs, and management implications.
745 citations
••
TL;DR: In biopsy-naïve men, the MRI pathway compared with the TRUSGB pathway results in an identical detection rate of csPCa, with significantly fewer insignPCa cases, in this high-quality standard study.
481 citations
••
TL;DR: The current RCT comparing ADT to ADT with EBRT to the prostate in patients with primary bone mPCa did not show a significant difference in overall survival, although the CI cannot exclude a substantial survival benefit.
348 citations
••
TL;DR: The emergence of new drugs for mCRPC has improved treatment options dramatically and the best strategies for patient selection and optimal sequential use to achieve the longest cumulative survival improvement and to prevent early resistance remain unclear.
313 citations
••
TL;DR: It is found that repeated screening reduces the risk of dying from prostate cancer and corroborate earlier results that PSA screening significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence.
305 citations
••
Katholieke Universiteit Leuven1, Netherlands Cancer Institute2, University of Bern3, University of Sheffield4, Medical University of Vienna5, Charité6, University of Bologna7, Vita-Salute San Raffaele University8, University of St. Gallen9, University of Manchester10, Monash University11, St James's University Hospital12, Wrightington, Wigan and Leigh NHS Foundation Trust13, Cardiff University14, Erasmus University Rotterdam15, McMaster University16, Aberdeen Royal Infirmary17, University of Aberdeen18
TL;DR: BCR has an impact on survival, but this effect appears to be limited to a subgroup of patients with specific clinical risk factors, which may form the basis of new BCR risk stratification (European Association of Urology BCR Risk Groups), which needs to be validated formally.
241 citations
••
TL;DR: It is reported that the presence of prostate-specific membrane antigen (PSMA) is extremely variable both within one patient and between different patients, and this may limit the usefulness of PSMA scans and PSMA-targeted therapies.
217 citations
••
TL;DR: This is the largest, most comprehensive examination of prostate cancer information on YouTube to date, including the first 150 videos on screening and treatment, used the validated DISCERN quality criteria for consumer health information and the Patient Education Materials Assessment Tool, and compared results for user engagement.
••
TL;DR: It is found that a good treatment response could be achieved in a subgroup of patients with few side effects, and that treatment outcome was worse in patients with organ metastases and elevated lactate dehydrogenase in blood tests.
••
TL;DR: BLCA can be stratified into six molecular subtypes with different overall survival (OS) and molecular features, and molecular subtyping is a promising way to tailor disease management for those who will benefit most.
••
TL;DR: It is found that extended removal of lymph nodes did not reduce the rate of tumor recurrence in the expected range and a larger trial is required to determine whether extended compared with limited LND leads to a small, but clinically relevant, survival difference.
••
TL;DR: The detection rates of (aggressive) prostate cancer among men with prior negative biopsies and a persistent suspicion of cancer using three different techniques of targeted biopsy based on magnetic resonance imaging were found to be no significant differences.
••
TL;DR: Multiparametric magnetic resonance imaging (MRI) and MRI-directed biopsies using the Prostate Imaging-Reporting and Data System improves the detection of prostate cancers likely to cause harm, and at the same time decreases the Detection of disease that does not lead to harms if left untreated.
••
TL;DR: As a new technique for surgical guidance, 99mTc-PSMA-RGS is feasible, and has been proved to be of high value for successful intraoperative detection and removal of metastatic lesions in PC patients scheduled for salvage surgery.
••
TL;DR: Prostate radiotherapy should be considered for men with mHSPC with a low metastatic burden, and in men with fewer than five bone metastases, addition of prostate radiotherapy helped them live longer and should be consider.
••
TL;DR: The first nomogram to predict lymph node invasion (LNI) in prostate cancer patients diagnosed via magnetic resonance imaging-targeted biopsy undergoing radical prostatectomy is developed.
••
Université Paris-Saclay1, Queen Mary University of London2, Ludwig Maximilian University of Munich3, University of Rennes4, University Medical Center Utrecht5, Charles University in Prague6, Hannover Medical School7, Aberdeen Royal Infirmary8, Umeå University9, University of Coimbra10, University of Eastern Piedmont11, Sheba Medical Center12, Lund University13, Royal Free Hospital14, Royal Free London NHS Foundation Trust15, Netherlands Cancer Institute16
TL;DR: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve).
••
TL;DR: OAB is seen as a complex, multifactorial symptom syndrome, resulting from multiple potential pathophysiological mechanisms, and there is a temptation to label OAB as "idiopathic" without obvious causation.
••
TL;DR: Magnetic resonance imaging of the prostate before surgical removal for prostate cancer finds less than half of all individual prostate cancer tumors and less than two-thirds of clinically significant CaP foci.
••
TL;DR: The treatment landscape for mccRCC has evolved since the introduction of VEGF inhibitors and combination therapies involving checkpoint inhibitors could be the next standard of care.
••
TL;DR: It is found that different areas from the same tumor are often molecularly different, particularly in the basal-squamous subtype, and this biological diversity must be taken into account when interpreting clinical molecular tests performed on bladder cancer samples.
••
TL;DR: Deleterious TSG variants are associated with an increased risk of relapse (L) and death (M1) in CSPC and these findings help identify patients with aggressive features who may benefit from intensified treatment.
••
TL;DR: After 3 yr of prostate-specific antigen (PSA) testing, it is demonstrated that after 3’yr of screening, more serious prostate cancers are detected in men with BRCA2 mutations than in those without these mutations.
••
TL;DR: The largest multi-institutional series to date reported long-term survival outcomes after RARC, and Stratified survival curves demonstrated poorer outcomes for positive SM, LN, and non-OC disease.
••
TL;DR: Mutation status of BRCA1/2 and ATM is associated with GR among men undergoing active surveillance, and men on active surveillance with inherited mutations in BRCa1/1 and ATM are more likely to harbor aggressive prostate cancer.
••
University of Manchester1, University of Salford2, University of Birmingham3, The Royal Marsden NHS Foundation Trust4, University College London5, Guy's and St Thomas' NHS Foundation Trust6, Institute of Cancer Research7, University of Bern8, University of Glasgow9, Beatson West of Scotland Cancer Centre10, Northampton Community College11, Cardiff University12
TL;DR: Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.
••
University of Aberdeen1, Aberdeen Royal Infirmary2, Utrecht University3, Cardiff University4, Erasmus University Rotterdam5, Lund University6, Institut Gustave Roussy7, Vita-Salute San Raffaele University8, University of Sheffield9, Royal Hallamshire Hospital10, Royal College of Surgeons in Ireland11, Charité12, Jikei University School of Medicine13, University of Zurich14, University of Bologna15, University of Manchester16, University of St. Gallen17, Netherlands Cancer Institute18, University of Bern19, Monash University20, St James's University Hospital21, Wrightington, Wigan and Leigh NHS Foundation Trust22, University of Washington23, Fred Hutchinson Cancer Research Center24, Katholieke Universiteit Leuven25, Robert Gordon University26, University of Canberra27, University of Paris28, University of Barcelona29, University of Lyon30, Brighton and Sussex Medical School31, Erasmus University Medical Center32, Radboud University Nijmegen33, Garvan Institute of Medical Research34, Copenhagen University Hospital35, University Hospital of Wales36, McMaster University37, University of Toronto38, Vanderbilt University Medical Center39, University College London40
TL;DR: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials.